ScreenerHero

CTNMContineum Therapeutics Inc. Class A Common Stock

NAS · US · Healthcare · Biotechnology · contineum-tx.com
17.19USD+7.30%Mkt Cap: 646.71M $P/E: —

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap646.71M $
Enterprise Value372.71M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.98M $
Revenue/Share—
Last Price17.19 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees51
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.91
PEG—
EV/EBITDA-5.65
EV/Revenue—
P/S—
P/B2.51
EPS (TTM)-1.72
EPS (Forward)-1.80
52W Range
7.26099% of range17.34
52W High17.34 USD
52W Low7.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.98%
ROA-21.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.31M $
CapEx (TTM)231.00K $
FCF Margin—
FCF Yield-5.43%
Net Debt-229.98M $
Net Debt/EBITDA3.48
Balance Sheet
Debt/Equity0.03
Current Ratio37.17
Quick Ratio36.25
Book Value/Sh6.372 USD
Cash/Share6.288 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.43 USD
Upside (mean)+36.3%
Target Range18.00 USD – 28.00 USD
$18.00+36.3% to mean$28.00
# Analysts7
Ownership
Shares Out.32.96M
Float27.82M
Insiders0.52%
Institutions93.08%
Short Interest
Short Ratio9.8d
Short % Float8.61%
Short % Out.7.50%
Shares Short2.82M
Short (prev mo.)2.14M
Technical
SMA 5014.30 (+20.2%)
SMA 20013.17 (+30.5%)
Beta0.74
S&P 52W Chg18.16%
Avg Vol (30d)398.31K
Avg Vol (10d)758.14K
Technical Indicators
RSI (14)65.3
MACD0.3876
MACD Signal0.2854
MACD Hist.+0.1021
BB Upper16.73 USD
BB Middle15.05 USD
BB Lower13.38 USD
BB Width22.30%
ATR (14)1.153 USD
Vol Ratio (20d)0.73x